GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker’s chief executive officer said.
The U.S. Food and Drug Administration plans to meet with top-level executives of e-cigarette makers, the agency’s chief said, hinting that some companies seem to be backing away from commitments related to youth’s access to e-cigarettes.
The former chief executive of Insys Therapeutics Inc. agreed to plead guilty to participating in a scheme to bribe doctors.
Forcing patients off opioid painkillers could sometimes do more harm than good, international medical experts warn in an open letter to health authorities.
An advisory panel to the U.S. Food and Drug Administration narrowly recommended prescribing the opioid overdose reversal drug naloxone along with addictive painkillers.
The U.S. Food and Drug Administration declined to approve an abuse-deterrent version of Mallinckrodt Plc’s opioid painkiller Roxicodone, saying some parts of the company’s application need further evaluation.
A former Insys Therapeutics Inc. sales representative now married to the drugmaker’s ex-CEO said she arranged to have a physician assistant in New Hampshire receive kickbacks to prescribe patients its addictive fentanyl spray.
A global coalition set up to fight disease epidemics is investing up to $8.4 million to develop a synthetic vaccine system that could be tailor-made to fight multiple pathogens such as flu, Ebola, Marburg and rabies.
More than 130,000 people were newly diagnosed with HIV last year in Eastern Europe – the highest rate ever for the region – while the number of new cases in Western Europe declined, global public health experts said.